← Back to patent-cliff list
Piperine
Tier C — Watch / tradePiperine
University Of Rochester
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：CYP3A, PGY1
Indications (approved)：Multiple myeloma, Prostate cancer, 意义未明单克隆免疫球蛋白血症, 阴燃多发性骨髓瘤
Regional status
US
Phase II
2021-12-14
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Piperine?
Approved indications include: Multiple myeloma, Prostate cancer, 意义未明单克隆免疫球蛋白血症, 阴燃多发性骨髓瘤.
When does the Piperine patent expire?
No public expiry year is available for Piperine yet; this page updates once verified.
How do I get a quote for Piperine intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06